Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Finalizing Risperdal Consta Resubmission; Approval Possible By Year-End

Executive Summary

Johnson & Johnson is finalizing its response to a Risperdal Consta "not approvable" letter received from FDA last year

You may also be interested in...



Risperdal Consta Priced Aggressively; J&J Sets High Premium To Zyprexa

Johnson & Johnson's Risperdal Consta (risperidone) is being launched at approximately twice the daily cost of Lilly's market-leading antipsychotic Zyprexa (olanzapine)

Risperdal Consta Priced Aggressively; J&J Sets High Premium To Zyprexa

Johnson & Johnson's Risperdal Consta (risperidone) is being launched at approximately twice the daily cost of Lilly's market-leading antipsychotic Zyprexa (olanzapine)

J&J Risperdal Consta Priced Comparable To Zyprexa; Clears FDA Oct. 29

Johnson & Johnson has room to price its long-acting risperidone injection Risperdal Consta 40% higher than Risperdal tablets, while still remaining comparable to Lilly's Zyprexa

Related Content

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel